bit.bio

The company's core business revolves around its proprietary cell coding platform, which facilitates the creation of consistent, scalable batches of any human cell type. This is achieved through a patented gene-targeting approach called opti-ox™ (optimised inducible overexpression). This technology reprograms human induced pluripotent stem cells (iPSCs) into specific, mature cell types by controlling the expression of key transcription factors. By overcoming the inconsistencies and scalability issues of traditional stem cell differentiation, bit.bio provides a reliable source of human cells for research, drug discovery, and the development of cell therapies. The business generates revenue by selling its cell products and through strategic partnerships with pharmaceutical and research organizations.

bit.bio's primary product line is marketed under the brand ioCells. This portfolio includes a variety of human cell types, such as nerve, immune, and muscle cells, available as wild-type cells, disease models, and CRISPR-ready cells for gene editing applications. These products offer researchers and drug developers access to physiologically relevant human cell models, aiming to bridge the 'translation gap' that often leads to high failure rates in clinical trials. The company's discovery platform utilizes genetic screening and machine learning to identify the precise transcription factor combinations required to create any desired cell type. Through collaborations with entities like BlueRock Therapeutics and Charles River Laboratories, bit.bio is expanding the application of its technology towards creating a new generation of medicines and cell therapies accessible to every patient.